Cyclacel Pharmaceuticals, Inc. (CYCC)

Market Cap	2.58M
Revenue (ttm)	74,000
Net Income (ttm)	-13.48M
Shares Out	6.94M
EPS (ttm)	-7.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	290,309
Open	0.375
Previous Close	0.374
Day's Range	0.359 - 0.392
52-Week Range	0.340 - 6.000
Beta	0.56
Analysts	Buy
Price Target	11.00 (+2,862.56%)
Earnings Date	Nov 12, 2024

About CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company’s lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kina...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: CYCC
• Website: https://www.cyclacel.com

Analyst Forecast

According to 2 analysts, the average rating for CYCC stock is "Buy." The 12-month stock price forecast is $11.0, which is an increase of 2,862.56% from the latest price.

Price Target

$11.0

(2,862.56% upside)

Analyst Consensus: Buy